Medical device startup CardioMech raised $13 million to advance the development and validation of its flagship device, which is designed to treat degenerative mitral valve regurgitation. The catheter-based device seeks to offer an uncomplicated, direct procedure for patients eligible for open-heart surgery as well as those considered eligible for the surgery.
Earlier this year, the Marlborough, Massachusetts-based medical device giant invested $90 million into Millipede with the option of acquiring the rest of the company,
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Edwards Lifesciences is paying up to $690 million to a buy an Israeli company that makes transcatheter mitral valve and tricuspid repair devices. Last year it bought a mitral valve replacement company for about $400 million.